Jason Najum has covered the psychedelic space for a long time and contextualizes recent news around the FDA, MDMA, PTSD and Lykos Therapeutics (1:35). Blessing in disguise for Cybin, COMPASS Pathways and MindMed (14:30)? Trial data and cash in the bank are top signifiers of success (22:35). How Atai fell behind and dropped out of the conversation (24:00). Upcoming catalysts - patience required (26:35). For psychedelic medicine, does it matter who's in the White House (29:30)?

Read episode transcripts

Show Notes:
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged
MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
ATAI: Enormous Potential Upside But No Clarity Yet
De-Risking Psychedelics: Compass Pathways, Cybin And Atai

For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Seeking Alpha. Innehållet i podden är skapat av Seeking Alpha och inte av, eller tillsammans med, Poddtoppen.